Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | BROCADE3: veliparib with carboplatin/paclitaxel in HER2-/BRCA+ advanced breast cancer

Véronique Dieras • 27 Sep 2019
ESMO 2019
Breast Cancer Carboplatin Paclitaxel Veliparib
BROCADE3

Véronique Dieras, MD, Eugène Marquis Center, Rennes, France, discusses the BROCADE3 trial (NCT02163694). This trial is investigating the efficacy and tolerability of veliparib vs. a placebo in combination with carboplatin and paclitaxel in HER2-negative metastatic or locally advanced, unresectable, BRCA-associated breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Véronique Dieras

0:58
TNBC treatment: platinum-based therapy and PARP inhibition
Véronique Dieras • 27 Sep 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals